GW Pharmaceuticals in Cambridge, which is developing drugs based on legalised cannabis, has received regulatory approval for its prescription medicine Sativex® in Switzerland.A full marketing authorisation has been granted by the Swissmedic authorities in the treatment of moderate to severe spasticity in Multiple Sclerosis patients who have not responded adequately to other anti-spasticity medications.
Launch timing is dependent on completion of pricing and reimbursement procedures. Sativex will be commercialised in Switzerland by GW’s European partner, Almirall S.A.
“This approval in Switzerland marks yet another regulatory success for Sativex, which is now approved in a total of 23 countries,” said Justin Gover, GW’s CEO. Sativex is approved for use in the treatment of MS spasticity in 23 countries, including 17 in Europe.
• PHOTOGRAPH SHOWS: Justin Gover